Target (CBDY) Non-Current Deffered Revenue (2019)

Target (CBDY) reported Non-Current Deffered Revenue of $1.3 million for Q4 2019, up 1.86% quarter-over-quarter from $1.3 million in Q3 2019.

Target (CBDY) Non-Current Deffered Revenue (2019) Analysis & Trends

Target (CBDY) has 1 years of Non-Current Deffered Revenue data on file, last reported at $1.3 million in Q4 2019.

Non-Current Deffered Revenue for Q4 2019 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $1.3 million (changed N/A YoY), and the FY2019 annual result was $1.3 million, changed N/A from the prior year.
Non-Current Deffered Revenue improved to $1.3 million in Q4 2019 per CBDY's latest filing, from $1.3 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $1.5 million in Q1 2019 and troughed at $1.3 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	-
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	-
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	-
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	-
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	-
10	Target	-	-	191,787.00	-

Download Data